In this week’s EuroBiotech Report, with AstraZeneca now back in play–if it chooses–talk of M&A involving European drugmakers has ratcheted up once again after a brief, post-Shire lull. And more. …read more Source: Ex-Shire exec starts at Cortendo, Innate gets orphan nod, Ablynx trims in preclinical
Shares of OncoMed Pharmaceuticals took a nasty tumble a couple of months ago when it hit the brakes on a pair of early-stage programs for two of its treatments after investigators noted trouble with some bone-related adverse events. Today, the biotech says it adjusted its protocols on vantictumab, a Wnt pathway inhibitor program, to the […]
Ted Tenthoff, an analyst for Piper Jaffray, was clearly pumped about the prospects of an Achillion buyout when a reporter from Bloomberg reached him. …read more Source: Back on the ‘hot’ list, Achillion shares spike (yet again) on takeover talk
Biotech investing is sizzling right now, and despite all the attention that the Boston hub gets, the Bay Area is still number one. …read more Source: What’s the #1 biotech hub for VCs? (It’s still not Boston)
The S-1 prominently features Civitas’ successful Phase IIb study for an inhaled formulation of levodopa, a “rescue” treatment for Parkinson’s patients. …read more Source: Parkinson’s play Civitas Therapeutics files for an $86M IPO
Arch Venture Partners has joined a lineup of top venture groups which has been making hay while the market sun shines on biotech IPOs. The VC has marshaled more than $400 million for its new investment fund–its eighth–that will now be available to back a new wave of cutting-edge life science companies, often starting from […]
Just 8 months after extending its last round with a $15 million raise, Houston-based Bellicum Pharmaceuticals has lured in a whole new group of backers to add $55 million to fuel its work. And the strategic financing allows the biotech to stare down a shot at an IPO while the window remains open. …read more […]
Novartis’ big generics operation at Sandoz has been one of the leaders in the field of biosimilar development. So when the chief lays out a timetable on the adoption of these long-awaited knockoffs of some of the industry’s biggest biologics, FierceBiotech listens. …read more Source: Novartis CEO predicts a looming biosimilars boom
Alkermes has taken another step toward the market with its long-acting version of the schizophrenia drug Abilify, filing for an approval with the FDA as it lays the foundation for a hoped-for launch in 2015. …read more Source: Alkermes closer to launching once-monthly schizophrenia drug into a crowded market
Civitas Therapeutics has nailed down a substantial $55 million venture round aimed at getting its lead program for Parkinson’s through Phase III and onto the market. The Chelsea, MA-based biotech is developing CVT-301, a fast-acting rescue formulation of levodopa that can be self-administered through an inhaler. …read more Source: Civitas nails $55M venture round for […]
